Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention

NCT05413551 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT05413551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05413551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
Lead sponsor
Stanford University
Phase
Phase 1
Overall status
Completed
Start date
March 23, 2023
Completion date
June 25, 2025
Enrollment
78 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

isoniazid adverse reaction, tuberculosis infection